The in vitro anticoagulant effect of abelacimab in healthy children

Safe and effective anticoagulants are crucial for managing thrombotic disorders, particularly in children. Although direct oral anticoagulants offer advantages, including predictable pharmacokinetics and minimal monitoring, their bleeding risks remain similar to traditional anticoagulants. Abelacimab, a novel, dual-acting monoclonal antibody targeting factor XI (FXI)/activated FXI, shows promise in providing the potential for antithrombotic efficacy while reducing bleeding risks in adults and warrants further investigation in children.

To investigate the in vitro age-related anticoagulant effect of abelacimab in healthy individuals from children to adults, before in vivo testing.

Citrated plasma samples from 60 healthy participants across 6 age groups (1-6 months, 6 months to 2 years, 2-6 years, 6-12 years, 12-18 years, and adults) were spiked with increasing concentrations of abelacimab (0, 0.3, 1.0, 3.0, 10, 30, and 100 μg/mL). Activated partial thromboplastin time and FXI coagulation activity were measured using commercially available reagents.

A sigmoidal, concentration-dependent increase in clotting time was observed across all age groups, with the 1- to 6-month age group exhibiting significantly prolonged clotting times compared with adults at most concentrations. FXI coagulation activity was comparable among all pediatric age groups and adults, with the exception of the 1- to 6-month age group.

In vitro findings indicate a predictable concentration-response to abelacimab, with significant pharmacodynamics differences in young children. In vivo studies are required to confirm these findings, optimize dosing, and assess clinical implications in the pediatric population.